Navegando por Palavras-chave "Prednisone"
Agora exibindo 1 - 4 de 4
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosColchicina no tratamento da oftalmopatias de Graves(Universidade Federal de São Paulo (UNIFESP), 2001) Stamato, Francisco Jose da Cunha [UNIFESP]; Furlanetto, Reinaldo Perrone [UNIFESP]
- ItemAcesso aberto (Open Access)Colchicine in the treatment of the inflammatory phase of Graves' ophthalmopathy: a prospective and randomized trial with prednisone(Conselho Brasileiro de Oftalmologia, 2006-12-01) Stamato, Francisco José da Cunha [UNIFESP]; Maciel, Rui Monteiro de Barros [UNIFESP]; Manso, Paulo Gois [UNIFESP]; Wolosker, Ângela Maria Borri [UNIFESP]; Paiva, Elias Rodrigues de [UNIFESP]; Lopes, Antonio Carlos [UNIFESP]; Furlanetto, Reinaldo Perrone [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)PURPOSE: To investigate if colchicine is valuable in the treatment of Graves' ophthalmopathy (GO), we compared its effect with prednisone in 22 patients during the inflammatory phase of GO. METHODS: All patients, similar in age, sex and smoking habits, were euthyroid for at least 3 months and randomly divided into two groups, one treated with colchicine (1.5 mg/day) and the other treated with prednisone (0.75 mg/kg/day). They were monitored with ophthalmologic assessment (clinical activity score-CAS) and magnetic resonance imaging, using a signal intensity ratio (SIR) of the recti muscles in comparison to the cerebral substantia alba. RESULTS: Amelioration of CAS was seen in 68% of the orbits in both groups. SIR also had a significant reduction after treatment: the initial median of 1.14 in G1 and 1.27 in G2, evolved, after treatment, to 1.07 in G1 and 0.69 in G2. The variation between both groups after treatment was not significant (p=0.22). None of the patients treated with colchicine had side effects; on the other hand, side effects in G2 were weight gain, edema, gastric complaints, hirsutism, weakness, depression, and alterations in blood pressure. CONCLUSION: Colchicine had a beneficial effect on the inflammatory phase of GO without the side effects of prednisone.
- ItemSomente MetadadadosHormone profile in juvenile systemic lupus erythematosus with previous or current amenorrhea(Springer, 2011-08-01) Silva, Clovis A.; Deen, Maria E. J.; Febronio, Marilia V.; Oliveira, Sheila K.; Terreri, Maria T. [UNIFESP]; Sacchetti, Silvana B.; Sztajnbok, Flavio R.; Marini, Roberto; Quintero, Maria V.; Bica, Blanca E.; Pereira, Rosa M.; Bonfa, Eloisa; Ferriani, Virginia P.; Robazzi, Teresa C.; Magalhaes, Claudia S.; Hilario, Maria O. [UNIFESP]; Universidade de São Paulo (USP); Rijks Univ Groningen; Universidade Federal do Rio de Janeiro (UFRJ); Universidade Federal de São Paulo (UNIFESP); Univ Estadual Rio Janeiro; Universidade Estadual de Campinas (UNICAMP); Pediat Rheumatol Unit; Hosp Sao RafaelTo identify the underlying mechanism of amenorrhea in juvenile systemic lupus erythematosus (JSLE) patients, thirty-five (11.7%) JSLE patients with current or previous amenorrhea were consecutively selected among the 298 post-menarche patients followed in 12 Brazilian pediatric rheumatology centers. Pituitary gonadotrophins [follicle-stimulating hormone (FSH) and luteinizing hormone (LH)] and estradiol were evaluated in 32/35 patients, and prolactin and total testosterone in 29/35 patients. Patient's medical records were carefully reviewed according to demographic, clinical and therapeutic findings. the mean duration of amenorrhea was 7.2 +/- A 3.6 months. Low FSH or LH was observed in 7/32 (22%) JSLE patients and normal FSH or LH in 25 (78%). Remarkably, low levels of FSH or LH were associated with higher frequency of current amenorrhea (57% vs. 0%, P = 0.001), higher median disease activity (SLEDAI) and damage (SLICC/ACR-DI) (18 vs. 4, P = 0.011; 2 vs. 0, P = 0.037, respectively) and higher median current dose of prednisone (60 vs. 10 mg/day, P = 0.0001) compared to normal FSH or LH JSLE patients. None of them had decreased ovarian reserve and premature ovarian failure. Six of 29 (21%) patients had high levels of prolactin, and none had current amenorrhea. No correlations were observed between levels of prolactin and SLEDAI, and levels of prolactin and SLICC/ACR-DI scores (Spearman's coefficient). We have identified that amenorrhea in JSLE is associated with high dose of corticosteroids indicated for active disease due to hypothalamic-pituitary-ovary axis suppression.
- ItemAcesso aberto (Open Access)Interação farmacocinética do tacrolimo: a influência de prednisona, ácido micofenólico ou sirolimo(Universidade Federal de São Paulo (UNIFESP), 2010-07-28) Park, Sung In [UNIFESP]; Pestana, Jose Osmar Medina [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Background & objective: This study was conducted to evaluate timedependent pharmacokinetic changes and drug interactions over the first 6 months after transplantation in kidney transplant recipients receiving tacrolimus, prednisone, and mycophenolate mofetil or sirolimus. Patients & Methods: Pharmacokinetic assessments were done at day 7 and months 1, 3, and 6 in kidney transplant recipients receiving tacrolimus plus prednisone with either mycophenolate mofetil (2 g/day, n=13) or sirolimus (15 mg loading dose, 5 mg for 7 days followed by 2 mg/day, n=12). Results & Discussion: There were no differences in main demographic characteristics or in mean prednisone doses during the first six months after transplant. From day 7 to month 6 there was a 65% increase in tacrolimus dose corrected exposure (dose corrected area under the curve) in patients receiving mycophenolate mofetil cotherapy (p= 0.005) and a 59% increase in tacrolimus dose corrected exposure in patients receiving sirolimus cotherapy (p=0.008). From day 7 to month 6 there was a 72% increase in mycophenolate dose corrected exposure (p=0.001) and a 65% increase in sirolimus dose corrected exposure (p=0.008). Tacrolimus dose corrected exposure was 23% lower in patients receiving sirolimus compared to mycophenolate mofetil (p=0.012) on average over the study period. Prednisone dose reduction was associated with increase in tacrolimus (in patients receiving sirolimus, p=0.040) and mycophenolic acid (p=0.070) drug exposures. Tercile distribution of tacrolimus drug exposure showed a positive correlation with mean sirolimus exposures (p=0.016). Conversely, tercile distribution of sirolimus drug exposure showed a positive correlation with mean tacrolimus exposures (p=0.004). Conclusions: Time-dependent increases in tacrolimus, mycophenolic acid and sirolimus drug exposures occur up to 6 months after transplantation. Significant drug-to-drug interactions indicate that intense therapeutic drug monitoring is required to avoid under- or over-immunosuppression.